PRNewsWire
28 Jul 2026, 08:08 UTC · 7h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
GRAIL, Inc. is facing a securities fraud class action lawsuit alleging it misled investors regarding the prospects of its NHS-Galleri trial. — Allegations of fraud and the concealment of adverse clinical trial data typically lead to investor distrust and downward pressure on stock prices.
-0.60The lawsuit claims GRAIL overstated the optimism of the NHS-Galleri study and ignored data suggesting a three-year timeframe was insufficient to meet the primary endpoint. — Specific claims about the failure to meet trial endpoints suggest the company's core product efficacy may be lower than marketed.
-0.50The class period for the alleged securities violations is defined as May 13, 2025, to February 19, 2026. — Defines the window of financial exposure and the specific group of affected shareholders, though it is less market-moving than the fraud claim itself.
-0.10Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a securities fraud class action lawsuit alleging false and misleading statements regarding clinical trial results.
The company is mentioned as the subject of a securities fraud class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
12h ago
